XORTX Therapeutics Inc.
XRTX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.14% | -2.36% | -3.43% | 0.40% | 1.25% |
| Depreciation & Amortization | -0.38% | 5.71% | -16.18% | -16.32% | -26.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.87% | -28.44% | -47.20% | -57.83% | -56.01% |
| Operating Income | 23.87% | 28.44% | 47.20% | 57.83% | 56.01% |
| Income Before Tax | -26.83% | 70.31% | -53.53% | 90.09% | 79.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.83% | 70.31% | -53.53% | 90.09% | 79.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.83% | 70.31% | -53.53% | 90.09% | 79.69% |
| EBIT | 23.87% | 28.44% | 47.20% | 57.83% | 56.01% |
| EBITDA | 11.56% | 18.70% | 39.99% | 58.32% | 56.47% |
| EPS Basic | -8.07% | 79.15% | -21.23% | 99.12% | 88.21% |
| Normalized Basic EPS | -8.02% | 79.15% | -21.24% | 99.11% | 88.21% |
| EPS Diluted | -8.16% | 79.02% | -20.48% | 99.12% | 88.16% |
| Normalized Diluted EPS | -8.02% | 79.15% | -21.24% | 99.11% | 88.21% |
| Average Basic Shares Outstanding | 46.88% | 52.15% | 45.25% | 36.17% | 34.04% |
| Average Diluted Shares Outstanding | 46.88% | 52.15% | 45.25% | 36.17% | 34.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |